• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

每日一次和每日两次给药方案获得的 7 天荨麻疹活动评分(UAS7)值的比较:ASSURE-CSU 研究结果。

Comparison of Urticaria Activity Score Over 7 Days (UAS7) Values Obtained from Once-Daily and Twice-Daily Versions: Results from the ASSURE-CSU Study.

机构信息

RTI Health Solutions, Research Triangle Park, NC, USA.

RTI Health Solutions, Manchester, UK.

出版信息

Am J Clin Dermatol. 2018 Apr;19(2):267-274. doi: 10.1007/s40257-017-0331-8.

DOI:10.1007/s40257-017-0331-8
PMID:29368043
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5978890/
Abstract

BACKGROUND

The Urticaria Activity Score summed over 7 days (UAS7) assesses the itch severity and hive count in chronic spontaneous urticaria (CSU) using once- or twice-daily diary-based documentation.

OBJECTIVE

The aim of this study was to evaluate the comparability of twice-daily versus once-daily versions of the UAS and the resulting UAS7 values.

METHODS

Data came from the ASSURE-CSU study. The twice-daily and once-daily UAS7 was calculated from morning and evening ratings, as well as from exact 24-h evening ratings of hive count and itch severity, respectively. Three UAS7 scores were computed: UAS7 twice daily (UAS7), UAS7 once daily for maximum itch (UAS7), and UAS7 once daily for average itch (UAS7). UAS7 values were assigned to five score bands (0, 1-6, 7-15, 16-27, 28-42), reflecting urticaria-free to severe disease activity. The score values and score band ratios of the UAS7 and UAS7 versions were compared and assessed for correlation by weighted Cohen's kappa statistics.

RESULTS

Data from 614 patients were analyzed. All three versions of the UAS7 yielded very similar results, with a mean (standard deviation) UAS7, UAS7, and UAS7 of 17.3 (10.49), 17.7 (8.90), and 16.2 (8.68), respectively. Correlation coefficients between UAS7 and UAS7, UAS7 and UAS7, and UAS7 and UAS7 were 0.94, 0.95, and 0.99, respectively, showing very high positive pairwise correlation. The weighted kappa coefficient, κ (95% confidence interval) was 0.78 (0.75-0.82) for UAS7 versus UAS7, and 0.82 (0.78-0.85) for UAS7 versus UAS7, demonstrating substantial agreement.

CONCLUSIONS

The once- and twice-daily UAS7 scores were highly consistent, supporting the use of either version when evaluating CSU activity.

摘要

背景

7 天荨麻疹活动评分(UAS7)通过每日一次或两次的日记记录来评估慢性自发性荨麻疹(CSU)的瘙痒严重程度和风团数量。

目的

本研究旨在评估 UAS 的每日两次和每日一次版本的可比性,以及由此产生的 UAS7 值。

方法

数据来自 ASSURE-CSU 研究。UAS7 的每日两次和每日一次版本分别根据早上和晚上的评分以及风团数量和瘙痒严重程度的准确 24 小时晚上评分计算得出。计算了三种 UAS7 评分:UAS7 每日两次(UAS7)、UAS7 每日一次以最大瘙痒(UAS7)和 UAS7 每日一次以平均瘙痒(UAS7)。UAS7 值被分配到五个评分区间(0、1-6、7-15、16-27、28-42),反映无荨麻疹至严重疾病活动。通过加权 Cohen's kappa 统计评估 UAS7 和 UAS7 版本的评分值和评分区间比值,并评估相关性。

结果

对 614 名患者的数据进行了分析。UAS7 的所有三个版本都产生了非常相似的结果,UAS7 的平均值(标准差)分别为 17.3(10.49)、17.7(8.90)和 16.2(8.68)。UAS7 与 UAS7、UAS7 与 UAS7 和 UAS7 与 UAS7 的相关系数分别为 0.94、0.95 和 0.99,显示出非常高的正相关性。UAS7 与 UAS7、UAS7 与 UAS7 的加权 kappa 系数,κ(95%置信区间)分别为 0.78(0.75-0.82)和 0.82(0.78-0.85),表明存在实质性一致性。

结论

每日一次和两次 UAS7 评分高度一致,支持在评估 CSU 活动时使用任一个版本。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e01d/5978890/3bdd036ea54b/40257_2017_331_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e01d/5978890/4b536f0c9cb8/40257_2017_331_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e01d/5978890/7301d656da20/40257_2017_331_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e01d/5978890/3bdd036ea54b/40257_2017_331_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e01d/5978890/4b536f0c9cb8/40257_2017_331_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e01d/5978890/7301d656da20/40257_2017_331_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e01d/5978890/3bdd036ea54b/40257_2017_331_Fig3_HTML.jpg

相似文献

1
Comparison of Urticaria Activity Score Over 7 Days (UAS7) Values Obtained from Once-Daily and Twice-Daily Versions: Results from the ASSURE-CSU Study.每日一次和每日两次给药方案获得的 7 天荨麻疹活动评分(UAS7)值的比较:ASSURE-CSU 研究结果。
Am J Clin Dermatol. 2018 Apr;19(2):267-274. doi: 10.1007/s40257-017-0331-8.
2
Comparison and interpretability of the available urticaria activity scores.可用荨麻疹活动评分的比较和可解释性。
Allergy. 2018 Jan;73(1):251-255. doi: 10.1111/all.13271. Epub 2017 Sep 18.
3
The Urticaria Activity Score-Validity, Reliability, and Responsiveness.荨麻疹活动评分的有效性、可靠性和反应性。
J Allergy Clin Immunol Pract. 2018 Jul-Aug;6(4):1185-1190.e1. doi: 10.1016/j.jaip.2017.10.001. Epub 2017 Nov 8.
4
Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria.慢性自发性/特发性荨麻疹疾病活动分类分析。
Br J Dermatol. 2017 Oct;177(4):1093-1101. doi: 10.1111/bjd.15454. Epub 2017 Sep 24.
5
Psychometric properties of the Spanish version of the once-daily Urticaria Activity Score (UAS) in patients with chronic spontaneous urticaria managed in clinical practice (the EVALUAS study).在临床实践中管理的慢性自发性荨麻疹患者中,一日一次荨麻疹活动评分(UAS)的西班牙语版本的心理测量特性(EVALUAS 研究)。
Health Qual Life Outcomes. 2019 Jan 31;17(1):23. doi: 10.1186/s12955-019-1087-z.
6
Validity and responsiveness of the Urticaria Activity and Impact Measure: A new patient-reported tool.荨麻疹活动和影响衡量标准的有效性和响应性:一种新的患者报告工具。
Ann Allergy Asthma Immunol. 2018 Jun;120(6):641-647. doi: 10.1016/j.anai.2018.03.012. Epub 2018 Mar 19.
7
Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.奥马珠单抗治疗 H1 抗组胺药治疗反应不佳的慢性自发性荨麻疹患者:IV 期开放标签 SUNRISE 研究结果。
Br J Dermatol. 2019 Jan;180(1):56-66. doi: 10.1111/bjd.16904. Epub 2018 Sep 17.
8
Chronic Urticaria Biomarkers IL-6, ESR and CRP in Correlation with Disease Severity and Patient Quality of Life-A Pilot Study.慢性荨麻疹生物标志物IL-6、血沉和C反应蛋白与疾病严重程度及患者生活质量的相关性——一项初步研究
Biomedicines. 2023 Aug 9;11(8):2232. doi: 10.3390/biomedicines11082232.
9
Omalizumab in chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response.奥马珠单抗治疗慢性自发性荨麻疹:疗效、安全性、治疗结果预测因素和起效时间。
Ann Allergy Asthma Immunol. 2018 Oct;121(4):474-478. doi: 10.1016/j.anai.2018.06.014. Epub 2018 Jun 24.
10
Serum Amyloid A as a Potential Biomarker for Disease Activity in Chronic Spontaneous Urticaria.血清淀粉样蛋白 A 作为慢性自发性荨麻疹疾病活动的潜在生物标志物。
J Allergy Clin Immunol Pract. 2024 Jan;12(1):195-200. doi: 10.1016/j.jaip.2023.09.004. Epub 2023 Sep 15.

引用本文的文献

1
A Comparison of Chronic Spontaneous Urticaria Clinical Characteristics and Management between Canadian and Israeli Adults.加拿大和以色列成年人慢性自发性荨麻疹临床特征与治疗的比较
Int Arch Allergy Immunol. 2025 Jul 24:1-6. doi: 10.1159/000547551.
2
Efficacy and safety of CT-P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16-week follow-up study.奥马珠单抗生物类似药CT-P39治疗慢性自发性荨麻疹的疗效与安全性:16周随访研究
Clin Transl Allergy. 2025 Jun;15(6):e70069. doi: 10.1002/clt2.70069.
3
Can urticaria severity be used as a biomarker for transition from acute to chronic urticaria?

本文引用的文献

1
The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU.慢性自发性荨麻疹负担沉重:ASSURE-CSU 的真实世界证据。
Allergy. 2017 Dec;72(12):2005-2016. doi: 10.1111/all.13209. Epub 2017 Jul 10.
2
Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria.慢性自发性/特发性荨麻疹疾病活动分类分析。
Br J Dermatol. 2017 Oct;177(4):1093-1101. doi: 10.1111/bjd.15454. Epub 2017 Sep 24.
3
Patient-reported outcomes in clinical practice.临床实践中患者报告的结局
荨麻疹严重程度能否作为急性荨麻疹转变为慢性荨麻疹的生物标志物?
Pediatr Allergy Immunol. 2025 Mar;36(3):e70053. doi: 10.1111/pai.70053.
4
Substantial psychosocial impairments in patients with chronic urticaria are associated with delayed referral to urticaria centers, non-academic treatments, and dietary changes.慢性荨麻疹患者存在显著的心理社会障碍,这与延迟转诊至荨麻疹中心、非专业治疗以及饮食改变有关。
Allergol Select. 2025 Feb 10;9:8-15. doi: 10.5414/ALX02554E. eCollection 2025.
5
Jujube Oxymel for the Treatment of Chronic Spontaneous Urticaria: Efficacy and Safety.枣子蜜治疗慢性自发性荨麻疹:疗效与安全性
Adv Biomed Res. 2024 Sep 23;13:91. doi: 10.4103/abr.abr_426_23. eCollection 2024.
6
Omalizumab in Chronic Spontaneous Urticaria: A Real-World Study on Effectiveness, Safety and Predictors of Treatment Outcome.奥马珠单抗治疗慢性自发性荨麻疹:一项关于有效性、安全性及治疗结果预测因素的真实世界研究
Clin Cosmet Investig Dermatol. 2024 Aug 7;17:1799-1808. doi: 10.2147/CCID.S470160. eCollection 2024.
7
The Efficacy and Safety of High Dose (10 mg) of Desloratadine (Dazit® 10) in the Treatment of Chronic Spontaneous Urticaria in India: A Phase III, Multicentric, Open-Label, Single-Arm Study.高剂量(10毫克)地氯雷他定(Dazit® 10)治疗印度慢性自发性荨麻疹的疗效与安全性:一项III期、多中心、开放标签、单臂研究。
Cureus. 2024 Jan 28;16(1):e53125. doi: 10.7759/cureus.53125. eCollection 2024 Jan.
8
Automatic Urticaria Activity Score: Deep Learning-Based Automatic Hive Counting for Urticaria Severity Assessment.自动荨麻疹活动评分:基于深度学习的自动风团计数用于荨麻疹严重程度评估。
JID Innov. 2023 Jul 12;4(1):100218. doi: 10.1016/j.xjidi.2023.100218. eCollection 2024 Jan.
9
Chronic Spontaneous Urticaria: How to Measure It and the Need to Define Treatment Success.慢性自发性荨麻疹:如何进行测量以及明确治疗成功标准的必要性。
Dermatol Ther (Heidelb). 2023 Aug;13(8):1629-1646. doi: 10.1007/s13555-023-00955-7. Epub 2023 Jun 24.
10
Association between serological indicators of past contacts with Herpesviridae and a slower resolution of chronic spontaneous urticaria in children.疱疹病毒既往接触的血清学指标与儿童慢性自发性荨麻疹缓解速度较慢的相关性。
Croat Med J. 2023 Apr 30;64(2):67-74. doi: 10.3325/cmj.2023.64.67.
Hematology Am Soc Hematol Educ Program. 2015;2015:501-6. doi: 10.1182/asheducation-2015.1.501.
4
ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria.ASSURE-CSU:一项关于有症状慢性自发性荨麻疹患者疾病负担的真实世界研究。
Clin Transl Allergy. 2015 Aug 17;5:29. doi: 10.1186/s13601-015-0072-9. eCollection 2015.
5
The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update.变应性接触性皮炎诊断和治疗的欧洲指南(2013 年版)
Allergy. 2014 Jul;69(7):868-87. doi: 10.1111/all.12313. Epub 2014 Apr 30.
6
Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria.慢性荨麻疹诊断和治疗国际指南的修订版。
J Dtsch Dermatol Ges. 2013 Oct;11(10):971-7; quiz 978. doi: 10.1111/ddg.12194. Epub 2013 Aug 19.
7
Demonstrating measurement equivalence of the electronic and paper formats of the Urticaria Patient Daily Diary in patients with chronic idiopathic urticaria.验证慢性特发性荨麻疹患者电子和纸质版荨麻疹患者日常日记的测量等效性。
Patient. 2013;6(3):225-31. doi: 10.1007/s40271-013-0021-4.
8
Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria.评估慢性特发性荨麻疹患者的荨麻疹活动评分和其他疾病活动衡量标准的最小重要差异。
Ann Allergy Asthma Immunol. 2012 Jan;108(1):20-24. doi: 10.1016/j.anai.2011.09.008. Epub 2011 Nov 2.
9
Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report.慢性自发性荨麻疹未满足的临床需求。GA²LEN 工作组报告。
Allergy. 2011 Mar;66(3):317-30. doi: 10.1111/j.1398-9995.2010.02496.x. Epub 2010 Nov 17.
10
Development of a daily diary for patients with chronic idiopathic urticaria.慢性特发性荨麻疹患者日记的开发。
Ann Allergy Asthma Immunol. 2010 Aug;105(2):142-8. doi: 10.1016/j.anai.2010.06.011.